39 Articles
39 Articles
Encapsulated stem cell–derived β cells exert glucose control in patients with type 1 diabetes
Clinical studies on the treatment of type 1 diabetes with device-encapsulated pancreatic precursor cells derived from human embryonic stem cells found that insulin output was insufficient for clinical benefit. We are conducting a phase 1/2, open-label, multicenter trial aimed at optimizing cell engraftment (ClinicalTrials.gov identifier: NCT03163511 ). Here we report interim, 1-year outcomes in one study group that received 2–3-fold higher cell …
Stem Cell-Derived Islets Still Producing Insulin at 1 Year
CHICAGO — Ten people with type 1 diabetes, who had recurrent severe hypoglycemia and hypoglycemic unawareness, have remained insulin-independent for over a year following allogeneic stem cell-derived islet-cell therapy with immunosuppression, according to new phase 1/2 data from the multicenter FORWARD study sponsored by Vertex Pharmaceuticals. The insulin-producing therapy VX-880, now named zimislecel, is delivered […] The post Stem Cell-Derive…
Coverage Details
Bias Distribution
- 89% of the sources are Center
To view factuality data please Upgrade to Premium